Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 8/20 | 0.47 |
| ▸ | RAB9A | P51151 | 6/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13370752 | 0.81 | TGFBR1 (0.43) | NPC1RAB9ASMN1; SMN2BCHEALDH1A1 | |
| SCHEMBL29614829 | 0.77 | NPC1 (0.63) | NPC1RAB9ASMN1; SMN2BCHEALDH1A1 | |
| SCHEMBL29942654 | 0.77 | NPC1 (0.63) | NPC1RAB9ASMN1; SMN2BCHEALDH1A1 | |
| SCHEMBL3076524 | 0.77 | NPC1 (0.63) | NPC1RAB9ASMN1; SMN2BCHEALDH1A1 | |
| SCHEMBL29966674 | 0.77 | NPC1 (0.63) | NPC1RAB9ASMN1; SMN2BCHEALDH1A1 | |
| SCHEMBL1789932 | 0.76 | NPC1 (0.46) | NPC1RAB9ASMN1; SMN2BCHEALDH1A1 | |
| SCHEMBL467101 | 0.76 | RAB9A (0.47) | NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL6097808 | 0.73 | NPC1 (0.46) | NPC1RAB9ASMN1; SMN2BCHEALDH1A1 | |
| SCHEMBL713067 | 0.72 | NPC1 (0.62) | NPC1RAB9ASMN1; SMN2BCHEALDH1A1 | |
| SCHEMBL714449 | 0.71 | PDGFRB (0.53) | NPC1RAB9AALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007135529-A2 | AZABENZIMIDAZOLYL COMPOUNDS AS MGLUR2 POTENTIATORS | PFIZER PRODUCTS INC. (US) | 2007-11-29 | — | — | WO | claimed |
| WO-2007135527-A2 | BENZIMIDAZOLYL COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2007-11-29 | — | — | WO | claimed |
| US-20230201161-A1 | Combination comprising HDAC inhibitor, LAG-3 inhibitor and a PD-1 inhibitor or PD-L1 inhibitor for cancer treatment | 4SC AG (DE) | 2023-06-29 | — | — | US | disclosed |
| US-20210145799-A1 | PHARMACEUTICAL COMBINATION PRODUCTS COMPRISING A HISTONE DEACETYLASE (HDAC) INHIBITOR AND A TLR7 AGONIST AND/OR TLR8 AGONIST FOR THE TREATMENT OF CANCER | 4SC AG (DE) | 2021-05-20 | — | — | US | disclosed |
| US-20210113528-A1 | Combination comprising HDAC inhibitor and CD137 agonist for cancer therapy | 4SC AG (DE) | 2021-04-22 | — | — | US | disclosed |
| WO-2021064188-A1 | COMBINATION COMPRISING HDAC INHIBITOR, CTLA-4 INHIBITOR AND A PD-1 INHIBITOR OR PD-L1 INHIBITOR FOR CANCER TREATMENT | 4SC AG (DE) | 2021-04-08 | — | — | WO | disclosed |
| CN-108299511-B | Organometallic iridium complex, light-emitting element, light-emitting device, and lighting device | 株式会社半导体能源研究所 | 2021-03-12 | — | — | CN | disclosed |
| EP-3781557-A1 | PHARMACEUTICAL COMBINATION PRODUCTS COMPRISING A HISTONE DEACETYLASE (HDAC) INHIBITOR AND A TLR7 AGONIST AND/OR TLR8 AGONIST FOR THE TREATMENT OF CANCER | 4SC AG (DE) | 2021-02-24 | — | — | EP | disclosed |
| EP-3781159-A1 | COMBINATION COMPRISING HDAC INHIBITOR, LAG-3 INHIBITOR AND A PD-1 INHIBITOR OR PD-L1 INHIBITOR FOR CANCER TREATMENT | 4SC AG (DE) | 2021-02-24 | — | — | EP | disclosed |
| EP-3773554-A1 | COMBINATION COMPRISING HDAC INHIBITOR AND CD137 AGONIST FOR CANCER THERAPY | 4SC AG (DE) | 2021-02-17 | — | — | EP | disclosed |
| EP-2478981-B1 | SILVER-(CONJUGATED COMPOUND) COMPLEX | SUMITOMO CHEMICAL CO (JP) | 2020-12-23 | — | — | EP | disclosed |
| US-7666868-B2 | e.g. N-Hydroxy-3-{1-[4-(1-methyl-1H-indol-5-yl)-benzenesulfonyl]-1H-pyrrol-3-yl}-acrylamide; antiproliferative, anticarcinogenic, antiinflammatory, neuroleptic agent, autoimmune disorders | 4SC AG (DE) | 2010-02-23 | — | — | US | disclosed |
| EP-1861365-B1 | N-SULPHONYLPYRROLES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS | 4SC AG (DE) | 2009-07-01 | — | — | EP | disclosed |
| US-20080176848-A1 | e.g. N-Hydroxy-3-{1-[4-(1-methyl-1H-indol-5-yl)-benzenesulfonyl]-1H-pyrrol-3-yl}-acrylamide; antiproliferative, anticarcinogenic, antiinflammatory, neuroleptic agent, autoimmune disorders | NYCOMED GMBH (DE) | 2008-07-24 | — | — | US | disclosed |
| CN-101137623-A | N-sulphonylpyrroles and their use as histone deacetylase inhibitors | NYCOMED GMBH (DE) | 2008-03-05 | — | — | CN | disclosed |
| EP-1861365-A1 | N-SULPHONYLPYRROLES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS | Nycomed GmbH (DE) | 2007-12-05 | — | — | EP | disclosed |
| WO-2007135527-A2 | BENZIMIDAZOLYL COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2007-11-29 | — | — | WO | disclosed |
| WO-2006097474-A1 | N-SULPHONYLPYRROLES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS | NYCOMED GMBH (DE) | 2006-09-21 | — | — | WO | disclosed |
| US-3923810-A | Perfluoroalkanesulfonamides N-substituted by heterocyclic groups | PBI-GORDON CORPORATION | 1975-12-02 | — | — | US | disclosed |
| US-3923811-A | Perfluoroalkanesulfonamides N-substituted by heterocyclic groups | PBI-GORDON CORPORATION | 1975-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210145799-A1 | PHARMACEUTICAL COMBINATION PRODUCTS COMPRISING A HISTONE DEACETYLASE (HDAC) INHIBITOR AND A TLR7 AGONIST AND/OR TLR8 AGONIST FOR THE TREATMENT OF CANCER | HDAC8, TLR8, TLR7 | NPC1 2449/4885RAB9A 3393/4885SMN1; SMN2 3801/4885 |
| US-20080176848-A1 | e.g. N-Hydroxy-3-{1-[4-(1-methyl-1H-indol-5-yl)-benzenesulfonyl]-1H-pyrrol-3-yl}-acrylamide; antiproliferative, anticarcinogenic, antiinflammatory, neuroleptic agent, autoimmune disorders | HDAC1, H1-3, HDAC2 | NPC1 4556/4885RAB9A 3521/4885SMN1; SMN2 2594/4885 |
| US-20210113528-A1 | Combination comprising HDAC inhibitor and CD137 agonist for cancer therapy | HDAC7, HDAC1, HDAC11 | NPC1 781/4885RAB9A 1453/4885SMN1; SMN2 3742/4885 |
| US-20230201161-A1 | Combination comprising HDAC inhibitor, LAG-3 inhibitor and a PD-1 inhibitor or PD-L1 inhibitor for cancer treatment | HDAC1, HDAC3, HDAC11 | NPC1 3699/4885RAB9A 1283/4885SMN1; SMN2 3003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.